International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD)- A Prospective Real-World Observational Study of Aducanumab-avwa in Patients With Alzheimer's Disease in the US
Latest Information Update: 23 Jun 2022
Price :
$35 *
At a glance
- Drugs Aducanumab (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms ICARE AD-US
- Sponsors Biogen
- 16 Jun 2022 Status changed from recruiting to discontinued.
- 26 Apr 2022 Trial design,presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 20 Dec 2021 Status changed from not yet recruiting to recruiting.